Relief Therapeutics Holding AG (RLFTF)

[mc67]

$RLFTF The Results


Trial 3 includes a series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP.
So far, 19 out of 21 of them have survived. At the moment, August 20, 7 patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. As often in those cases, blood oxygenation is very low and can be lethal.

As you can see below, the use of RLF-100™, dramatically improved blood oxygenation.

A promising anti-COVID drug you have probably never heard of

https://medium.com/@alexschroeti/a-promising-anti-covid-drug-you-have-probably-never-heard-of-d6cae8072da6